Nonsteroid antiinflammatory drugs in endothelial dysfunction correction in women with arterial hypertension

Forty eight women (middle age 55,92±1,56) took part in the study. Presence of arterial hypertension for not less than 3- 5 years was considered to be an essential criterion of inclusion. The patients were divided into 2 groups, in the first group the antihypertension therapy was added by blocker COX-1 acetilsalicylic acid at a dose of 150 mg (Cardiomagnyl, "NYCOMED DANMARK, ApS") once a day, in the second group - by inhibitor COX-2 celecoxib (Celebrex, "SEARLE division of Monsanto pls") at a daily dose of 200 mg. The term of dynamic supervision was 2 weeks of active therapeutic intervention. The intensity of inflammation was estimated according to the level of sICAM-1 and CRP; functional condition of endothelium was estimated according to endothelium-dependent vasodilatation (EDVD) using ultrasound of high permission. The methods of variation statistics were used in statistical processing. The research showed that arterial hypertension was accompanied by ED. The use of nonsteroid antiinflammatory drugs, irrespective of tropism to forms of cyclooxygenases, leads to reduction of endothelial dysfunction in patients with AH.